These findings suggest that there are multiple genetic mechanisms contributing to the pathogenesis of AdCC that emphasize a complex genetic landscape of this tumor and point to potential targets for therapy beyond the canonical MYB/MYBL1::NFIB fusion (10). The gene discussed is NFIB; the disease is adrenocortical carcinoma, hereditary.